No change to product information for breast cancer medicine Tyverb following re-assessment of data

View source ↗

Summary

European Medicines Agency states there is no change to the product information for the breast cancer medicine Tyverb after a re-assessment of data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tyverb (lapatinib)